as well as its Intravenous Choline Chloride therapy for patients requiring parenteral support. In the recent earnings report, Protara Therapeutics revealed key financial highlights for the quarter ...

On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to report interim ...

The 10.3% of participants that experienced recrudescence -- recurrent malaria caused by the same strain of P. falciparum as ...

This study found artemisinin partial resistance in Ugandan children with complicated malaria associated with the Pfkelch13 A675V variation and also found suboptimal 28-day efficacy of parenteral ...

Etiology and Treatment Advances of Hematochezia in Infants Aged ≤3 Months. Journal of Biosciences and Medicines, 12, 273-285. doi: 10.4236/jbm.2024.1211023 . Acute intussusception is most prevalent in ...

Corstasis to present pivotal trial data on Bumetanide Nasal Spray at AHA 2024, highlighting safety, and efficacy. #AHA2024.

0.908 Parenteral antibiotics within 48 h of ICU admission, n (%) 127 (89.4) 282 (80.5) 0.0169 APACHE = Admission Acute Physiologic and Chronic Health Evaluation II; CRRT = continuous renal ...

A study conducted in Uganda has found evidence of partial resistance to the primary treatment for malaria in young children ...

The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.

Fresenius Kabi, an operating company of Fresenius, announced today it received a Novaplus Program Excellence Award from Vizient, Inc., the nation's largest provider-driven healthcare performance ...

ASCO-ONS standards for the administration of antineoplastic therapy provide a framework for ensuring patient safety.